Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$1.46
+0.3%
$1.75
$1.26
$5.20
$156.72M1.2777,269 shs1,321 shs
Relx Nv stock logo
RENX
Relx
$21.19
$0.00
$20.06
$23.30
N/AN/A100,590 shs547,934 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MaxCyte, Inc. stock logo
MXCT
MaxCyte
0.00%+2.84%+6.62%-35.27%-64.02%
Relx Nv stock logo
RENX
Relx
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$1.46
+0.3%
$1.75
$1.26
$5.20
$156.72M1.2777,269 shs1,321 shs
Relx Nv stock logo
RENX
Relx
$21.19
$0.00
$20.06
$23.30
N/AN/A100,590 shs547,934 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MaxCyte, Inc. stock logo
MXCT
MaxCyte
0.00%+2.84%+6.62%-35.27%-64.02%
Relx Nv stock logo
RENX
Relx
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MaxCyte, Inc. stock logo
MXCT
MaxCyte
2.50
Moderate Buy$7.00382.76% Upside
Relx Nv stock logo
RENX
Relx
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest YGEN, OSL, MXCT, and RENX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2025
MaxCyte, Inc. stock logo
MXCT
MaxCyte
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyNeutral
8/7/2025
MaxCyte, Inc. stock logo
MXCT
MaxCyte
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform
7/22/2025
MaxCyte, Inc. stock logo
MXCT
MaxCyte
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$6.00
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$38.63M4.00N/AN/A$1.95 per share0.74
Relx Nv stock logo
RENX
Relx
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$41.06M-$0.43N/AN/AN/A-125.22%-22.12%-19.10%11/5/2025 (Estimated)
Relx Nv stock logo
RENX
Relx
N/A$1.2217.37N/AN/AN/AN/AN/A

Latest YGEN, OSL, MXCT, and RENX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.10-$0.12-$0.02-$0.12$9.57 million$8.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/AN/AN/AN/AN/A
Relx Nv stock logo
RENX
Relx
$0.281.32%N/A22.95%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/A
12.40
11.71
Relx Nv stock logo
RENX
Relx
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
MaxCyte, Inc. stock logo
MXCT
MaxCyte
68.81%
Relx Nv stock logo
RENX
Relx
1.37%

Insider Ownership

CompanyInsider Ownership
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.30%
Relx Nv stock logo
RENX
Relx
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
MaxCyte, Inc. stock logo
MXCT
MaxCyte
80106.61 million103.09 millionOptionable
Relx Nv stock logo
RENX
Relx
N/AN/AN/ANot Optionable

Recent News About These Companies

Reba McEntire & Rex Linn Are Engaged!

New MarketBeat Followers Over Time

Media Sentiment Over Time

MaxCyte stock logo

MaxCyte NASDAQ:MXCT

$1.46 +0.01 (+0.34%)
As of 09:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Relx stock logo

Relx NYSE:RENX

RELX NV, through its interest in RELX Group plc, provides information and analytics for professional and business customers across industries worldwide. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment offers information and analytics to institutions and professionals. The Risk & Business Analytics segment provides solutions and decision tools that combine public and industry specific content with technology and analytics to evaluate and predict risk, as well as enhance operational efficiency. The Legal segment offers legal, regulatory, and business information and analytics. The Exhibitions segment is involved in the events business. The company was formerly known as Reed Elsevier NV and changed its name to RELX NV in June 2015. RELX NV was incorporated in 1880 and is headquartered in Amsterdam, the Netherlands.